NCT03029325

Brief Summary

Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15,000

participants targeted

Target at P75+ for all trials

Timeline
4mo left

Started Jun 1993

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Jun 1993Sep 2026

Study Start

First participant enrolled

June 1, 1993

Completed
22.3 years until next milestone

First Submitted

Initial submission to the registry

September 30, 2015

Completed
1.3 years until next milestone

First Posted

Study publicly available on registry

January 24, 2017

Completed
9.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

November 29, 2024

Status Verified

November 1, 2024

Enrollment Period

33.3 years

First QC Date

September 30, 2015

Last Update Submit

November 26, 2024

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (1)

  • Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression

    Study lung cancer development in a case control study. We will look at three separate outcome measures specified below

    20 years

Secondary Outcomes (3)

  • Overall survival

    20 years

  • Progression-free survival

    20 years

  • Treatment toxicities

    20 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Lung cancer cases and healthy controls are recruited from Massachusetts General Hospital patient population. Cases come from Thoracic Surgery or Cancer Center. Controls are usually spouses or friends of cases, or in some cases unrelated to a specific case.

You may qualify if:

  • healthy controls: participants without evidence of any cancer
  • cases: pathology proven primary lung cancer

You may not qualify if:

  • younger than 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood and tissue samples

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • David C Christiani, MD

    Harvard TH Chan School of Public Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

David Christiani, MD

CONTACT

617-726-9274dchris@hsph.harvard.edu

Andrea Shafer, MPH

CONTACT

6177269274ashafer@mgh.harvard.edu

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Elkan Blout Professor at Harvard TH Chan School of Public Health, Professor of Medicine Harvard Medical School

Study Record Dates

First Submitted

September 30, 2015

First Posted

January 24, 2017

Study Start

June 1, 1993

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

November 29, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations

US(1)